Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zura Bio (ZURA)
NASDAQ:ZURA
Holding ZURA?
Track your performance easily
ZURA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.67 - $6.35
Previous CloseN/A
Volume136.30K
Average Volume (3M)591.56K
Market Cap
$112.30M
Enterprise Value$184.14M
Total Cash (Recent Filing)$729.22K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Mar 27, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding65,293,530
10 Day Avg. Volume398,409
30 Day Avg. Volume591,564
Standard Deviation0.22
R-Squared0.00007
Alpha-0.00955
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.64
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.71
Forecast
1Y Price Target
$14.50Price Target Upside738.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Zura Bio News
PremiumCompany Announcements
Zura Bio Highlights Strategic Goals and Clinical Advances
PremiumCompany Announcements
Zura Bio Initiates Global Phase 2 TibuSURE Study
PremiumCompany Announcements
Zura Bio to Present at Healthcare Conference
PremiumCompany Announcements
Zura Bio Announces Phase 2 Tibulizumab Study
PremiumCompany Announcements
Zura Bio Limited: Q3 2024 Financial Insights and Strategic ProgressBulls Say, Bears Say
Bulls Say
Clinical DevelopmentZURA's lead asset, tibulizumab, is an anti-IL-17/BAFF bispecific antibody entering Phase 2 trials in systemic sclerosis and hidradenitis suppurativa, potentially well-positioned to treat these complex autoimmune diseases.
Financial StabilityThe cash position of $188 million is expected to support ZURA's operations through 2027, providing financial stability for ongoing and future projects.
Regulatory ProgressZura has submitted an Orphan Drug Designation (ODD) request to the FDA, indicating potential for special status and benefits.
Bears Say
Clinical DataLackluster clinical data with no clear dose-dependent response in B cell count reductions and an increase in IL-17A target engagement observed at the highest dose in the post-dosing follow-up period.
Corporate DecisionsLilly's decision to out-license tibulizumab to Zura after Phase 1 studies raises concerns.
Regulatory And Approval ChallengesA 20% probability of approval is ascribed to tibulizumab in both systemic sclerosis as well as hidradenitis suppurativa, reflecting uncertainty about its success.
---
Ownership Overview
7.83% Insiders
2.52% Mutual Funds
43.43% Other Institutional Investors
41.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ZURA FAQ
What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was $1.67 and its highest was $6.35 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is $112.30M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s upcoming earnings report date is Mar 27, 2025 which is in 55 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Nov 07, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.131 by -$0.129.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.16.
How many shares outstanding does Zura Bio have?
Zura Bio has 65,293,530 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.131. Following the earnings report the stock price went up 3.953%.
Which hedge fund is a major shareholder of Zura Bio?
Among the largest hedge funds holding Zura Bio’s share is RA Capital Management. It holds Zura Bio’s shares valued at 13M.
---
Zura Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.50 (738.15% Upside)
$14.50 (738.15% Upside)
Blogger Sentiment
Bullish
ZURA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 25.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $2.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days >0.1%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.67%
12-Months-Change
Fundamentals
Return on Equity
-41.44%
Trailing 12-Months
Asset Growth
80.77%
Trailing 12-Months
Company Description
Zura Bio
JATT Acquisition Corp is a blank check company. It is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
---
ZURA Stock 12 Month Forecast
Average Price Target
$14.50
▲(738.15% Upside)
Technical Analysis
Best Analysts Covering ZURA
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-48.70%
reiterated a buy rating 9 months ago
Copying Steven Seedhouse's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -48.70% per trade.
---